Physician profile
Brock King
NPI 1154323921
$26,562.00
in general payments reported to CMS, 2019-2025
45 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 75% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $348 · 2021: $217 · 2022: $21K · 2023: $2,310 · 2024: $466 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,825 · Travel and Lodging: $1,209 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,824.64 |
| Travel and Lodging | $1,208.51 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $22,776.24 | 2022-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $1,031.24 | 2022-2025 | Signia |
| Medical Device Business Services, INC. | $595.77 | 2019 | |
| Tela Bio, INC. | $334.04 | 2023-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $292.18 | 2019-2025 | Echelon; Endopath |
| Baudax Bio INC. | $182.87 | 2020-2021 | |
| Smith+Nephew, INC. | $136.49 | 2019-2025 | Grafix Pl, Stravix |
| Davol INC. | $87.79 | 2020-2022 | |
| Polynovo North America LLC | $71.61 | 2023-2024 | Novosorb Btm |
| Abbvie INC. | $65.34 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $56.95 | 2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $56.85 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.52 | 2023-2024 | Gattex |
| Acera Surgical, INC. | $50.07 | 2019-2021 | |
| Angiodynamics, INC. | $50.00 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48.16 | 2021-2024 | Wegovy |
| Lemaitre Vascular, INC. | $47.86 | 2019-2025 | Artegraft Vascular Graft |
| Pacira Pharmaceuticals Incorporated | $47.70 | 2022-2025 | Exparel |
| Baxter Healthcare | $41.08 | 2020 | |
| Tas Medical, INC. | $38.92 | 2024 | |
| Hologic Sales and Service, LLC | $38.81 | 2023-2024 | Localizer, Magseed |
| Endologix LLC | $35.40 | 2019 | |
| Silk Road Medical, INC. | $33.54 | 2020-2021 | |
| Solventum Corporation | $31.56 | 2024-2025 | Prevena, V.A.C. Veraflo Cleanse Choice, V.A.C.Ulta |
| Kci USA, INC. | $28.57 | 2021-2023 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Integra Lifesciences Corporation | $27.58 | 2022 | |
| Bard Peripheral Vascular, INC. | $25.67 | 2020 | |
| Allergan, INC. | $20.83 | 2021 | |
| Heron Therapeutics, INC. | $20.44 | 2023 | Zynrelef |
| Paratek Pharmaceuticals, INC. | $19.96 | 2019 | |
| Misonix INC | $19.11 | 2020 | |
| W. L. Gore & Associates, INC. | $18.77 | 2025 | Gore Enform Preperitoneal Biomaterial |
| Acell, INC. | $18.06 | 2019 | |
| Innocoll Pharmaceuticals Limited | $16.56 | 2022 | |
| Shield Therapeutics INC | $16.42 | 2023 | Accrufer |
| Z-Medica, LLC | $16.26 | 2019 | |
| Organogenesis INC. | $15.12 | 2021 | |
| Medtronic USA, INC. | $15.01 | 2020 | |
| Boston Scientific Corporation | $13.63 | 2024 | Varithena Administration Pack |
| Ambu INC. | $13.59 | 2023 | |
| Olympus America INC. | $13.57 | 2019 | |
| Teleflex LLC | $13.02 | 2021 | |
| Medtronic Vascular, INC. | $11.56 | 2019 | |
| Becton, Dickinson and Company | $11.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150,807.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.